Online inquiry

IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7483MR)

This product GTTS-WQ7483MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TGFB1&TGFB2&TGFB3 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000660.7; NM_001135599.4; NM_001329938.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7040; 7042; 7043
UniProt ID P01137; P61812; P10600
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7483MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7197MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ11995MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MM-121
GTTS-WQ2975MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ANB020
GTTS-WQ4449MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-734016
GTTS-WQ14968MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SHR-1314
GTTS-WQ14259MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RG-7116
GTTS-WQ11230MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI3902
GTTS-WQ11000MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCDS0593A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW